| Investor | Sio Capital Management, LLC |
13D/G Filings
This page shows a list of all the recent 13D/G filings made by Sio Capital Management, LLC . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).
When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.
| Date | Form | Target | Prev Shares |
Current Shares |
Change (Percent) |
Ownership (Percent) |
Change (Percent) |
|
|---|---|---|---|---|---|---|---|---|
| 2026-05-04 | 13G | SER / Serina Therapeutics, Inc. | 1,000,000 | |||||
| 2026-05-04 | 13G/A | AVR / Anteris Technologies Global Corp. | 1,772,601 | 5,382,965 | ||||
| 2026-05-04 | 13G/A | PMVP / PMV Pharmaceuticals, Inc. | 2,636,548 | 3,076,580 | ||||
| 2026-02-11 | 13G | ADGM / Adagio Medical Holdings, Inc. | 1,288,461 | |||||
| 2026-02-11 | 13G/A | ALGS / Aligos Therapeutics, Inc. | 355,937 | 335,937 | ||||
| 2025-11-12 | 13G/A | APRE / Aprea Therapeutics, Inc. | 279,369 | 112,223 | ||||
| 2025-11-12 | 13G/A | PMVP / PMV Pharmaceuticals, Inc. | 3,735,396 | 2,636,548 | ||||
| 2025-11-12 | 13G/A | NMTC / NeuroOne Medical Technologies Corporation | 3,523,663 | 2,360,635 | ||||
| 2025-11-12 | 13G/A | DRUG / Bright Minds Biosciences Inc. | 512,338 | 190,764 | ||||
| 2025-11-12 | 13G/A | AVR / Anteris Technologies Global Corp. | 2,934,027 | 1,772,601 | ||||
| 2025-08-13 | 13G/A | DRUG / Bright Minds Biosciences Inc. | 507,562 | 512,338 | ||||
| 2025-08-13 | 13G/A | PMVP / PMV Pharmaceuticals, Inc. | 3,735,396 | 3,735,396 | ||||
| 2025-08-13 | 13G | ALGS / Aligos Therapeutics, Inc. | 355,937 | |||||
| 2025-08-13 | 13G | NMTC / NeuroOne Medical Technologies Corporation | 3,523,663 | |||||
| 2025-08-13 | 13G/A | AVR / Anteris Technologies Global Corp. | 3,464,965 | 2,934,027 | ||||
| 2025-08-13 | 13G/A | APRE / Aprea Therapeutics, Inc. | 276,603 | 279,369 | ||||
| 2025-04-08 | 13G | VXRT / Vaxart, Inc. | 11,515,315 | 5,583,448 | ||||
| 2025-04-08 | 13G | QTTB / Q32 Bio Inc. | 697,413 | 0 | ||||
| 2025-04-08 | 13G | PMVP / PMV Pharmaceuticals, Inc. | 3,572,167 | 3,735,396 | ||||
| 2025-04-08 | 13G/A | APRE / Aprea Therapeutics, Inc. | 280,000 | 276,603 | ||||
| 2025-04-08 | 13G/A | VTYX / Ventyx Biosciences, Inc. | 4,046,797 | 2,582,655 | ||||
| 2025-04-08 | 13G | AVR / Anteris Technologies Global Corp. | 3,465,005 | 3,464,965 | ||||
| 2025-04-08 | 13G | DRUG / Bright Minds Biosciences Inc. | 451,793 | 507,562 | ||||
| 2025-02-10 | 13G | VTYX / Ventyx Biosciences, Inc. | 4,046,797 | |||||
| 2025-02-10 | 13G | PMVP / PMV Pharmaceuticals, Inc. | 3,572,167 | |||||
| 2025-02-10 | 13G | VXRT / Vaxart, Inc. | 11,515,315 | |||||
| 2025-02-10 | 13G/A | MODD / Modular Medical, Inc. | 2,110,260 | 251,990 | ||||
| 2025-02-10 | 13G | QTTB / Q32 Bio Inc. | 697,413 | |||||
| 2025-02-10 | 13G | AVR / Anteris Technologies Global Corp. | 3,465,005 | |||||
| 2025-02-10 | 13G | DRUG / Bright Minds Biosciences Inc. | 451,793 | |||||
| 2025-02-10 | 13G/A | 280,000 | 276,603 | |||||
| 2024-02-14 | 13G | GRCL / Gracell Biotechnologies Inc. - Depositary Receipt (Common Stock) | 25,007,900 | |||||
| 2024-02-14 | 13G/A | MODD / Modular Medical, Inc. | 1,091,479 | 2,110,260 | ||||
| 2024-02-14 | 13G | APRE / Aprea Therapeutics, Inc. | 280,000 | |||||
| 2023-02-13 | 13G | MODD / Modular Medical, Inc. | 1,091,479 | |||||
| 2022-02-10 | 13G/A | SLRX / Salarius Pharmaceuticals, Inc. | 1,657,242 | 1,354,291 | ||||
| 2022-02-10 | 13G/A | CLRB / Cellectar Biosciences, Inc. | 2,331,123 | 0 | ||||
| 2022-02-10 | 13G/A | CRIS / Curis, Inc. | 4,756,438 | 3,866,645 | ||||
| 2021-02-16 | 13G/A | LRMR / Larimar Therapeutics, Inc. | 2,283,164 | 188,661 | ||||
| 2021-02-16 | 13G | CLRB / Cellectar Biosciences, Inc. | 2,331,123 | |||||
| 2021-02-16 | 13G | SLRX / Salarius Pharmaceuticals, Inc. | 1,657,242 | |||||
| 2021-02-16 | 13G | CRIS / Curis, Inc. | 4,756,438 | |||||
| 2020-02-14 | 13G/A | BNGO / Bionano Genomics, Inc. | 714,842 | 1,210,821 | ||||
| 2020-02-14 | 13G | LRMR / Larimar Therapeutics, Inc. | 2,283,164 | |||||
| 2020-02-14 | 13G | TRIL / Tidal Trust II - Defiance Trillion Dollar Club Index ETF | 2,751,186 | |||||
| 2020-02-14 | 13G/A | BBI / Brickell Biotech Inc | 0 | |||||
| 2020-02-14 | 13G/A | ACHV / Achieve Life Sciences, Inc. | 597,373 | 0 | ||||
| 2019-02-14 | 13G | ACHV / Achieve Life Sciences, Inc. | 597,373 | |||||
| 2019-02-14 | 13G | BBI / Brickell Biotech Inc | 1,615,887 | |||||
| 2019-02-14 | 13G | BNGO / Bionano Genomics, Inc. | 714,842 | |||||
| 2019-02-14 | 13G | ACHV / Achieve Life Sciences, Inc. | 597,373 | |||||
| 2018-02-14 | 13G | QTNT / Quotient Ltd | 2,237,771 | 1,426,125 | ||||
| 2018-02-14 | 13G | CBIO / Crescent Biopharma, Inc. | 168,000 | 202,281 | ||||
| 2017-04-19 | 13G | CBIO / Crescent Biopharma, Inc. | 168,000 | |||||
| 2017-02-14 | 13G/A | ADMP / Adamis Pharmaceuticals Corp | 1,318,630 | 1,051,063 | ||||
| 2017-02-14 | 13G/A | QTNT / Quotient Ltd | 1,789,156 | 2,237,771 | ||||
| 2017-02-14 | 13G/A | MTEM / Molecular Templates, Inc. | 4,003,992 | 0 | ||||
| 2016-02-16 | 13G/A | QTNT / Quotient Ltd | 1,789,156 | |||||
| 2016-02-16 | 13G/A | ADMP / Adamis Pharmaceuticals Corp | 1,318,630 | |||||
| 2016-02-16 | 13G | MTEM / Molecular Templates, Inc. | 4,003,992 | |||||
| 2015-02-17 | 13G | ADMP / Adamis Pharmaceuticals Corp | 1,168,566 | |||||
| 2015-02-17 | 13G | QTNT / Quotient Ltd | 1,656,449 | |||||
| 2014-12-05 | 13G | ADMP / Adamis Pharmaceuticals Corp | 1,168,566 |
